Alnylam Pharmaceuticals’ (ALNY) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a report issued on Friday,Benzinga reports. Chardan Capital currently has a $300.00 price target on the biopharmaceutical company’s stock.

Several other equities analysts have also weighed in on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $310.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 26th. Canaccord Genuity Group lifted their target price on shares of Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the company a “buy” rating in a report on Tuesday, February 18th. Bank of America lifted their target price on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a “buy” rating in a report on Friday. Morgan Stanley lifted their target price on shares of Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an “equal weight” rating in a report on Friday, February 14th. Finally, Sanford C. Bernstein cut their target price on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating for the company in a report on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $310.22.

Alnylam Pharmaceuticals Stock Performance

ALNY opened at $283.34 on Friday. Alnylam Pharmaceuticals has a 12-month low of $141.98 and a 12-month high of $304.39. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. The firm has a market capitalization of $36.68 billion, a PE ratio of -130.57 and a beta of 0.39. The firm has a 50 day moving average of $257.16 and a two-hundred day moving average of $259.65.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). On average, analysts anticipate that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insiders Place Their Bets

In other news, CMO Pushkal Garg sold 52,592 shares of the business’s stock in a transaction dated Monday, January 27th. The shares were sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the transaction, the chief marketing officer now owns 11,989 shares of the company’s stock, valued at approximately $3,416,865. The trade was a 81.44 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Phillip A. Sharp sold 11,250 shares of the business’s stock in a transaction dated Thursday, January 23rd. The shares were sold at an average price of $275.00, for a total transaction of $3,093,750.00. The disclosure for this sale can be found here. Insiders have sold a total of 71,234 shares of company stock valued at $19,958,097 in the last 90 days. 1.50% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Allworth Financial LP boosted its position in shares of Alnylam Pharmaceuticals by 6.8% during the 4th quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company’s stock valued at $140,000 after acquiring an additional 38 shares during the last quarter. Investment Management Corp of Ontario boosted its position in shares of Alnylam Pharmaceuticals by 0.6% during the 4th quarter. Investment Management Corp of Ontario now owns 7,099 shares of the biopharmaceutical company’s stock valued at $1,670,000 after acquiring an additional 40 shares during the last quarter. Nixon Peabody Trust Co. boosted its position in shares of Alnylam Pharmaceuticals by 1.9% during the 4th quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company’s stock valued at $540,000 after acquiring an additional 43 shares during the last quarter. Brevan Howard Capital Management LP boosted its position in shares of Alnylam Pharmaceuticals by 3.4% during the 4th quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company’s stock valued at $314,000 after acquiring an additional 44 shares during the last quarter. Finally, IFP Advisors Inc boosted its position in shares of Alnylam Pharmaceuticals by 24.2% during the 4th quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company’s stock valued at $57,000 after acquiring an additional 47 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.